ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (1796–1826) Epidemiology & Public Health Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1796
Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)
Abstract Number: 1797
Factors Associated with Distress Related to Perceived Dignity in Patients with Rheumatic Diseases
Abstract Number: 1798
Association Between Knee Osteoarthritis and Mortality: A Serial Propensity Score-matched Cohort Study
Abstract Number: 1799
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
Abstract Number: 1800
Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Abstract Number: 1801
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Abstract Number: 1802
Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database
Abstract Number: 1803
Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress
Abstract Number: 1804
Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women
Abstract Number: 1805
Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Abstract Number: 1806
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Abstract Number: 1807
Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty
Abstract Number: 1808
Tobacco Smoking Reduces the Incidence and Delays the Progression of Knee Osteoarthritis: 10-year Retrospective Cohort Study Based on Korea National Health Insurance Service-Health Screening Database
Abstract Number: 1809
Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases
Abstract Number: 1810
Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Abstract Number: 1811
Strong Relationships Between Body Component Changes and Serum Uric Acid Variability
Abstract Number: 1812
Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Abstract Number: 1813
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Abstract Number: 1814
Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry
Abstract Number: 1815
The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Abstract Number: 1816
Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Abstract Number: 1817
Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Abstract Number: 1818
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Abstract Number: 1819
Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data
Abstract Number: 1820
Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study
Abstract Number: 1821
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Abstract Number: 1822
The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Abstract Number: 1823
Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia
Abstract Number: 1824
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Abstract Number: 1825
Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada
Abstract Number: 1826
Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology